Skip to nav Skip to content

Clinical Trial Search

287 Clinical Trials Found

Clinical Trial 22557

Disease Site: Non-Hodgkin's Lymphoma
PI: Jain, Michael

Clinical Trial 21721

A Randomized Double-Blind Trial of Abatacept Extended Dosing Versus Abatacept Short-Term Dosing for Graft Versus Host Disease Prophylaxis: "ABA3"
Disease Site: Unknown Sites
PI: Pidala, Joseph

Clinical Trial 21892

A Phase 2, Single-Arm, Open-Label Study using Itacitinib and Tafasitamab as Pre-Modulation in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Receiving CAR-T-Cell Therapy
Disease Site: Non-Hodgkin's Lymphoma
PI: Jain, Michael

Clinical Trial 22286

Disease Site: Leukemia, other
PI: Shah, Bijal

Clinical Trial 22485

Disease Site: Lip, Oral Cavity and Pharynx
PI: Chung, Christine

Clinical Trial 21131

A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features
Disease Site: Larynx, Lip, Oral Cavity and Pharynx, Head & Neck, Mouth, lip, nasal cavity
PI: Kirtane, Kedar

Clinical Trial 21378

Phase 1 Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab / Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer
Disease Site: Breast
PI: Han, Heather

Clinical Trial 20530

Multicenter, Phase II, Neoadjuvant and Adjuvant Study of Alectinib, Entrectinib, or Vemurafenib Plus Cobimetinib in Patients with Stages I-III Non-Small Cell Lung Cancer with ALK, ROS1, NTRK, or BRAF V600E Molecular Alterations
Disease Site: Lung
PI: Saltos, Andreas

Clinical Trial 22595

Disease Site: Multiple Myeloma
PI: Paba Prada, Claudia

Clinical Trial 20831

A Phase 1b/3 Double-Blind, Randomized,Active-Controlled, 3-Stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination with Lenalidomide Plus Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma
Disease Site: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
PI: Gaballa, Sameh

Clinical Trial 20386

Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 20339

Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
Disease Site: Bones and Joints, Rhabdomyosarcoma
PI: Metts, Jonathan